You are here: Industry Insights > Novo Nordisk

News List

Innate Pharma acquires anti-C5aR antibody from Novo Nordisk pharmaceutical-technology
June 06, 2017
French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m.
FDA approves new Novo Nordisk treatment for patients with Hemophilia biospectrumasia
June 02, 2017
REBINYN is indicated for on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding in adults and children with hemophilia B
Novo Nordisk posts 5-percent rise in Q1 firstwordpharma
May 04, 2017
Novo Nordisk announced Wednesday that first-quarter sales rose 5 percent year-over-year to 28.5 billion Danish kroner ($4.2 billion), above analyst estimates of 27.9 billion kroner ($4.1 billion), boosted by sales of diabetes and obesity therapies.
Fiasp - a new, ultra-fast acting mealtime insulin cphi-online
March 29, 2017
Novo Nordisk has announced that Fiasp, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada.
New economic data finds Novo Nordisk’s insulin degludec most cost effective diabetic treatment europeanpharmaceuticalreview
March 15, 2017
A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk‘s Tresiba (insulin degludec) is a cost-effective option for people living with type 1 and type 2 diabetes compared to insulin glargine U100 (Lantus).
Novo Nordisk eyes acquisition of Global Blood Therapeutics pharmafile
March 10, 2017
Novo Nordisk has been notoriously shy when it comes to making acquisitions but Reuters has reported ...
Novo Nordisk appoints new executive vice president biospectrumasia
March 08, 2017
Jakob Riis will remain with Novo Nordisk in a transition period to help ensure a smooth handover
Novo Nordisk's head of North American operations resigns firstwordpharma
March 02, 2017
Novo Nordisk announced Wednesday that Jakob Riis, head of the company's operations in North America, has resigned from his position. The drugmaker noted that Doug Langa, who currently serves as senior vice president for market access, has been appointed a
New-generation mealtime insulin approved in Europe cphi-online
January 16, 2017
Novo Nordisk to launch Fiasp in first half of 2017.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page